New mRNA drug offers hope for cystic fibrosis patients with no other options
Disease control
Recruiting now
This study tests an experimental mRNA medicine called ARCT-032 in 33 adults with cystic fibrosis who cannot take standard CFTR modulators. The goal is to see if the drug is safe and can improve lung function and quality of life. Participants receive multiple doses, and researcher…
Phase: PHASE2 • Sponsor: Arcturus Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 04:34 UTC